Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs Australia-based Phase 2a clinical study to evaluate broad-spectrum influenza vaccine candidate, OVX836 in combination with Quadrivalent Influenza Vaccines (QIVs) An enrollment of over 500 participants across Australia is anticipated Lyon, France – June 15, 2023 – Osivax, a biopharmaceutical company developing …
Archives de l’auteur : Marianne Duparc
World Congress Vaccine Washington 2023
Washington, DC – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Phase 2 immunogenicity results on OVX836 first-in-class broad-spectrum influenza vaccine in elderly patients”.
En bref : Cellprothera, Osivax, Confo Therapeutics, Daiichi Sankyo
Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine
Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine A Bill & Melinda Gates Foundation grant will be used to expand research and development of OVX836 in a wide range of seasonal and highly pathogenic influenza strains Osivax continues evaluating OVX836 across several phase 2 clinical trials in healthy volunteers …
Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors
Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors Company honors Dr. Michael Watson for his significant impact as member of Board of Directors Lyon, France – February 23, 2023 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment …
